Novo Nordisk partners with WeightWatchers to expand Wegovy access

PLAINSBORO, N.J. - Novo Nordisk announced today a new collaboration with WeightWatchers to expand patient access to its FDA-approved weight loss medication Wegovy (semaglutide) beginning July 1, 2025. The company, which has demonstrated impressive revenue growth of 24% over the last twelve months and maintains a strong gross profit margin of 85%, continues to strengthen its market position. According to InvestingPro, Novo Nordisk maintains a "GREAT" financial health rating, indicating robust operational performance.

Under the agreement, WeightWatchers will work with CenterWell Pharmacy to manage prescription fulfillment and delivery through NovoCare Pharmacy, aiming to provide patients with more streamlined access to the medication along with lifestyle support.

"We understand that how people choose to receive care is changing, and in response to that we are collaborating with WeightWatchers to deliver more accessible care to those living with chronic obesity," said Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk Inc.

The company will also introduce a limited-time offer of $299 for new self-paying patients from July 1 through July 31, 2025. After this period, the price will increase to $499 per month. This follows the expiration of a previous $199 offer ending June 30. Based on InvestingPro’s Fair Value analysis, Novo Nordisk’s stock appears slightly overvalued at current levels, though the company’s strong financial metrics and growth trajectory continue to attract investor attention.

Patients can access the new pricing through multiple channels including Wegovy.com, telehealth providers integrated with NovoCare Pharmacy, or directly through NovoCare Pharmacy.

Novo Nordisk emphasized that with all doses of FDA-approved Wegovy now fully available nationwide, it continues to pursue legal action against entities selling unauthorized "semaglutide" products. The company has filed nearly 120 lawsuits across 34 states against entities marketing or selling what it describes as knockoff drugs.

The FDA has previously issued warnings about risks associated with compounded "semaglutide" products, noting that serious patient illnesses and deaths have been linked to poor quality compounded drugs.

Wegovy is an injectable prescription medicine used with diet and exercise for weight management and to reduce cardiovascular risk in certain patients.

This announcement comes as Novo Nordisk continues existing collaborations with telehealth providers Ro and LifeMD, according to the company’s press release statement.

In other recent news, Novo Nordisk has terminated its partnership with Hims & Hers Health, Inc. over concerns related to semaglutide, a key ingredient in its weight management drug, Wegovy. The pharmaceutical company cited "deceptive promotion and selling of illegitimate, knockoff versions" of semaglutide as the reason for ending the collaboration. Novo Nordisk emphasized the importance of providing patients with authentic, FDA-approved Wegovy, highlighting safety concerns with foreign-sourced ingredients, particularly from China, that have not been authorized by the FDA. Additionally, Novo Nordisk has initiated legal actions against entities involved in the production and distribution of counterfeit semaglutide, filing nearly 120 lawsuits across 34 states. The company is also offering a promotional price for FDA-approved Wegovy to encourage patients to transition from unapproved versions. This initiative is part of their "Choose the Real Thing" campaign, aimed at educating the public about the risks of using non-approved drugs. These developments come as the FDA ends its grace period for mass compounding of semaglutide, making the production or sale of non-approved versions illegal under US compounding laws.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.